Clinical trials
Observational Neoplasms trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2010 | 1 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Unknown status | 8 |
| Recruiting | 4 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 2 |
| AstraZeneca | 2 |
| Barretos Cancer Hospital | 2 |
| Federal University of Minas Gerais | 2 |
| Grupo de Apoio ao Adolescente e a Crianca com Cancer | 2 |
| Instituto Brasileiro de Controle do Cancer | 2 |
| Instituto do Cancer do Estado de São Paulo | 2 |
| University of Nove de Julho | 2 |
| University of Sao Paulo | 2 |
| AC Camargo Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 34 |
| Breast Neoplasms | 3 |
| Acquired Immunodeficiency Syndrome | 2 |
| Cardiovascular Diseases | 2 |
| Malnutrition | 2 |
| Postoperative Complications | 2 |
| Radiation Injuries | 2 |
| Radiodermatitis | 2 |
| Sarcopenia | 2 |
| Acute Coronary Syndrome | 1 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.